• Oncology
  • Exited

CoStim is a biotechnology company focused on harnessing a patient’s own immune system by blocking the suppressive signals from cancer that shut down the immune response. CoStim has late discovery stage immunotherapy programs directed to several targets, including PD-1. CoStim was founded by MPM and leading researchers from Dana-Farber Cancer Center and Brigham and Women’s Hospital. CoStim was acquired by Novartis in 2014.